{"id":975,"date":"1999-10-01T12:05:00","date_gmt":"1999-10-01T10:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/behandlung-der-erektilen-dysfunktion"},"modified":"1999-10-01T12:05:00","modified_gmt":"1999-10-01T10:05:00","slug":"behandlung-der-erektilen-dysfunktion","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/behandlung-der-erektilen-dysfunktion","title":{"rendered":"Behandlung der erektilen Dysfunktion"},"content":{"rendered":"<p>Im Auftrag der Kommission Hormontoxikologie der Deutschen Gesellschaft f\u00fcr Endokrinologie berichteten k\u00fcrzlich C. Rolf und E. Nieschlag in den Endokrinologie-lnformationen (1999, Heft 4, S. 126) \u00fcber M\u00f6glichkeiten zur Behandlung der insbesondere bei \u00e4lteren M\u00e4nnern h\u00e4ufigen erektilen Dysfunktion (ED). Das Thema ist durch das seit einiger Zeit auch in Deutschland zugelassene Sildenafil (Viagra) popul\u00e4r geworden (s.a. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im Auftrag der Kommission Hormontoxikologie der Deutschen Gesellschaft f\u00fcr Endokrinologie berichteten k\u00fcrzlich C. Rolf und E. Nieschlag in den Endokrinologie-lnformationen (1999, Heft 4, S. 126) \u00fcber M\u00f6glichkeiten zur Behandlung der insbesondere bei \u00e4lteren M\u00e4nnern h\u00e4ufigen erektilen Dysfunktion (ED). Das Thema ist durch das seit einiger Zeit auch in Deutschland zugelassene Sildenafil (Viagra) popul\u00e4r geworden (s.a. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2483,507,2484,510,2486,2419,2485,806,2482,567,1117],"class_list":["post-975","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-alprostadil","tag-erektile-dysfunktion","tag-hyperprolaktinaemie","tag-impotenz","tag-muse","tag-prazosin","tag-prostaglandin-e1","tag-sildenafil","tag-skat","tag-testosteron","tag-yohimbin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/975","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=975"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/975\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=975"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=975"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=975"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}